An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Genvor Incorporated (OTCQB: GNVR) announces the unveiling of the latest research on patented peptides for Aflatoxin resistance in corn at the BioAgTech World Congress. The research, enabled by an R&D agreement with USDA's Agricultural Research Service, aims to address critical agricultural issues. The company's CEO, Chad Pawlak, emphasizes the importance of combating Aflatoxin contamination in corn, highlighting the potential impact of their peptide-based solutions. Genvor's collaboration with USDA and ongoing research efforts demonstrate a commitment to advancing sustainable plant health solutions.
Genvor Incorporated (OTCQB: GNVR) annuncia la presentazione delle ultime ricerche sui peptidi brevettati per la resistenza all'Aflatossina nel mais durante il Congresso Mondiale di BioAgTech. La ricerca, resa possibile da un accordo di R&S con il Servizio di Ricerca Agricola dell'USDA, mira a risolvere problemi agricoli critici. Il CEO dell'azienda, Chad Pawlak, sottolinea l'importanza di combattere la contaminazione da Aflatossina nel mais, evidenziando l'impatto potenziale delle loro soluzioni basate sui peptidi. La collaborazione di Genvor con l'USDA e i continui sforzi di ricerca dimostrano un impegno verso il progresso di soluzioni sostenibili per la salute delle piante.
Genvor Incorporated (OTCQB: GNVR) anuncia la presentación de las últimas investigaciones sobre péptidos patentados para la resistencia a la Aflatoxina en maíz en el Congreso Mundial de BioAgTech. La investigación, habilitada por un acuerdo de I+D con el Servicio de Investigación Agrícola del USDA, tiene como objetivo abordar problemas críticos en la agricultura. Chad Pawlak, el CEO de la compañía, enfatiza la importancia de combatir la contaminación por Aflatoxina en el maíz, destacando el impacto potencial de sus soluciones basadas en péptidos. La colaboración de Genvor con el USDA y los esfuerzos continuos de investigación demuestran un compromiso con el avance de soluciones sostenibles para la salud de las plantas.
Genvor Incorporated (OTCQB: GNVR)는 BioAgTech 세계 콩그레스에서 옥수수의 아플라톡신 저항성을 위한 특허받은 펩타이드에 대한 최신 연구를 발표합니다. 이 연구는 USDA의 농업 연구 서비스와의 연구 개발 협약에 의해 가능해졌으며, 중요한 농업 문제를 해결하려고 합니다. 회사의 CEO인 Chad Pawlak은 옥수수에서 아플라톡신 오염과 싸우는 것의 중요성을 강조하며, 그들의 펩타이드 기반 솔루션의 잠재적 영향을 강조합니다. Genvor의 USDA와의 협력 및 지속적인 연구 노력은 지속 가능한 식물 건강 솔루션 발전에 대한 헌신을 보여줍니다.
Genvor Incorporated (OTCQB: GNVR) annonce la présentation des dernières recherches sur les peptides brevetés pour la résistance à l'Aflatoxine dans le maïs au Congrès Mondial de BioAgTech. La recherche, rendue possible par un accord de R&D avec le Service de Recherche Agricole de l'USDA, vise à aborder des problèmes agricoles critiques. Le PDG de l'entreprise, Chad Pawlak, souligne l'importance de lutter contre la contamination par l'Aflatoxine dans le maïs, en mettant en évidence l'impact potentiel de leurs solutions à base de peptides. La collaboration de Genvor avec l'USDA et les efforts de recherche continus démontrent un engagement envers l'avancement de solutions durables pour la santé des plantes.
Genvor Incorporated (OTCQB: GNVR) kündigt die Präsentation der neuesten Forschungsergebnisse zu patentierten Peptiden für die Aflatoxin-Resistenz in Mais beim Weltkongress für BioAgTech an. Die Forschung, ermöglicht durch eine F&E-Vereinbarung mit dem landwirtschaftlichen Forschungsdienst der USDA, zielt darauf ab, kritische landwirtschaftliche Probleme anzugehen. Der CEO des Unternehmens, Chad Pawlak, betont die Bedeutung der Bekämpfung von Aflatoxin-Kontamination in Mais und hebt die potenzielle Wirkung ihrer peptidbasierten Lösungen hervor. Genvors Zusammenarbeit mit dem USDA und laufende Forschungsbemühungen zeigen ein Engagement für die Förderung nachhaltiger Lösungen für die Pflanzengesundheit.
Positive
None.
Negative
None.
Genvor's Research Enabled by R&D Agreement with USDA's Agricultural Research Service, Focused on Driving Solutions to the Nation's Most Pressing Agricultural Problems
CHAPEL HILL, NC / ACCESSWIRE / April 22, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant health solutions leveraging patented peptides, today announced that management will unveil the latest efficacy research regarding the use of peptides for Aflatoxin resistance in corn at the Company's booth at the 5th Annual BioAgTech World Congress - taking place in Raleigh, North Carolina, from April 22-26, 2024.
The BioAgTech World Congress is a leading event for industry innovators, dedicated to showcasing the latest technological advances. The research to be presented stems from Genvor's Cooperative Research & Development Agreement with the USDA's Agricultural Research Service, which conducts research to develop solutions to agricultural problems of a high national priority.
Pictured Above: Corn seeds and plants, fortified with Genvor's disease fighting peptides, in a USDA research facility in New Orleans, Louisiana.
Chad Pawlak, Chief Executive Officer of Genvor, commented: "Aflatoxin contamination is a significant issue facing American corn farmers, presenting a critical threat to both human and livestock health that is estimated to cause $500 million in damage to U.S. crops each year. The science backing our peptide-based approach to crop disease is sound - and with the support of the resources backing the USDA's Agricultural Research Service - our technology could play a significant role in the future of row crop production.
"To that end, our team recently completed a site visit to the USDA's Southern Regional Research Center in New Orleans, Louisiana - where transgenic corn fortified with Genvor's patented peptides is currently undergoing greenhouse trials - to evaluate research results and discuss next steps. We look forward to continuing our research with the USDA in the months ahead - including with additional crops - while concurrently furthering our active commercial discussions with potential industry partners for the various peptides in our robust portfolio," concluded Pawlak.
About Genvor
Genvor Incorporated (OTCQB:GNVR) is a developer of sustainable plant health solutions, with a portfolio of patented peptides to provide crops with anti-pathogen and enhanced nutritional properties through next-generation biological foliar application as well as transgenic seed traits. Supported by globally renowned scientists and a USDA partnership, Genvor leverages its licensing-first business model with active trait developments underway for a variety of crops including corn, citrus, rice, cotton, soybean, flax, and potato. To learn more, please visit www.genvor.com or follow us on LinkedIn, Facebook or Instagram.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include information about management's view of the Company's future expectations, plans and prospects, including future business opportunities or strategies and are generally preceded by words such as "may," "believe," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of known and unknown risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Certain of these risk factors and others are included in documents the Company files with the Securities and Exchange Commission, including but not limited to, the Company's most recent Annual Report on Form 10-K, as well as the Company's other reports filed with the Securities and Exchange Commission.
